RELAPSED/REFRACTORY MULTIPLE MYELOMA
Clinical trials for RELAPSED/REFRACTORY MULTIPLE MYELOMA explained in plain language.
Never miss a new study
Get alerted when new RELAPSED/REFRACTORY MULTIPLE MYELOMA trials appear
Sign up with your email to follow new studies for RELAPSED/REFRACTORY MULTIPLE MYELOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Off-the-Shelf CAR t cells show promise for Hard-to-Treat myeloma
Disease control CompletedThis early-phase study tested a new type of CAR T cell therapy, called ALLO-715, in 73 adults with multiple myeloma that had returned or stopped responding to at least three prior treatments. Unlike standard CAR T cells made from a patient's own cells, ALLO-715 is made from a hea…
Matched conditions: RELAPSED/REFRACTORY MULTIPLE MYELOMA
Phase: PHASE1 • Sponsor: Allogene Therapeutics • Aim: Disease control
Last updated May 17, 2026 07:36 UTC
-
New drug safety check for advanced blood cancer patients
Disease control CompletedThis study looked at the safety of the drug Kyprolis (carfilzomib) in 101 Indian patients whose multiple myeloma had come back or stopped responding to treatment. Researchers tracked side effects and how long patients lived without their cancer getting worse. The goal was to conf…
Matched conditions: RELAPSED/REFRACTORY MULTIPLE MYELOMA
Phase: PHASE4 • Sponsor: Amgen • Aim: Disease control
Last updated May 14, 2026 12:06 UTC